24 recruiting, 23 active not recruiting, 15 completed, 8 terminated. 53 Phase 2, 31 Phase 1, 11 Phase 3.
Follow Regn2810: new trials by email Literature Review of Regn2810 trials Research Report on Regn2810
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma Actinium Ac 225 Lintuzumab, Biospecimen Collection, Cemiplimab - Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 30 | 2026-12-04 | 2026-06-12 |
| A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC) Cemiplimab, Vidutolimod, Fianlimab - Locally Advanced Basal Cell Carcinoma | Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 135 | 2026-11-13 | 2026-10-30 |
| Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma Biopsy Procedure, Biospecimen Collection, Carboplatin - Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 108 | 2026-09-01 | 2026-10-05 |
| A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma Cemiplimab, Cemiplimab+Fianlimab Fixed Dose Combination (FDC) - High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 120 | 2026-08-31 | 2026-05-05 |
| Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer Biospecimen Collection, Cemiplimab, Cetuximab Sarotalocan Sodium - Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2026-08-15 | 2026-09-15 | |
| Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer Biopsy Procedure, Biospecimen Collection, Cemiplimab - Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 86 | 2026-08-10 | 2026-09-09 |
| REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336 - Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 265 | 2026-07-20 | 2026-09-28 |
| Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer Oxaliplatin, Capecitabine, Cemiplimab - Colorectal Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 66 | 2026-07-14 | 2026-07-21 |
| Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 44 | 2026-05-27 | 2026-10-26 |
| Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma Cemiplimab Plus Gemcitabine - Pancreatic Ductal Adenocarcinoma (mPDAC) | Phase 2 | Recruiting | University of California, San Diego | 43 | 2026-05-06 | 2026-06-08 |
| Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer Biospecimen Collection, Carboplatin, Cemiplimab - Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 180 | 2026-04-24 | 2026-10-26 |
| A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma FDC fianlimab+cemiplimab, Cemiplimab, Placebo - Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 120 | 2026-04-14 | 2026-10-22 |
| Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer Biospecimen Collection, Cabozantinib, Cemiplimab - Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 48 | 2026-02-22 | 2026-11-06 |
| Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer Biopsy, Biospecimen Collection, Cemiplimab - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 11 | 2026-01-30 | 2026-05-20 |
| Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma Biopsy Procedure, Biospecimen Collection, Cemiplimab - Metastatic NUT Carcinoma, Unresectable NUT Carcinoma | Phase 2 | Recruiting | Northwestern University | 15 | 2025-08-15 | 2026-08-18 |
| PALACE: Cemiplimab Trial According to ctDNA Levels Cemiplimab, Carboplatin, Paclitaxel - Non Small Cell Lung Cancer Metastatic, Lung Diseases | Phase 2 | Recruiting | Fundación GECP | 63 | 2025-07-29 | 2025-11-19 |
| Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer Ubamatamab, Bevacizumab, Cemiplimab - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 397 | 2025-05-28 | 2026-11-06 |
| Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) Biospecimen Collection, Cemiplimab, Computed Tomography - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 / Phase 3 | Recruiting | SWOG Cancer Research Network | 378 | 2025-05-22 | 2026-10-09 |
| Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer Biospecimen Collection, Cemiplimab, Fianlimab - Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 60 | 2025-05-02 | 2026-10-29 |
| Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer Biospecimen Collection, Cemiplimab, Computed Tomography - Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain | Phase 2 | Withdrawn | City of Hope Medical Center | 2025-04-15 | 2025-05-26 |
Showing 20 of 84. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (15) · Neoplasm Metastasis (9) · Carcinoma, Basal Cell (7) · Lung Neoplasms (7) · Melanoma (7) · Recurrence (7) · Squamous Cell Carcinoma of Head and Neck (7) · Ovarian Neoplasms (5) · Skin Neoplasms (5) · Fallopian Tube Neoplasms (4) · Neoplasms (4) · Adenocarcinoma (3) · Carcinoma (3) · Colorectal Neoplasms (3) · Glioblastoma (3)
Regeneron Pharmaceuticals (50) · National Cancer Institute (NCI) (7) · Mayo Clinic (3) · City of Hope Medical Center (2) · Emory University (2) · M.D. Anderson Cancer Center (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · University of Southern California (2) · Alaunos Therapeutics (1) · Columbia University (1) · Fundación GECP (1) · Inovio Pharmaceuticals (1) · Marcelo Bonomi (1) · Mark Stein (1) · Northwestern University (1)
United States (69) · Spain (23) · Australia (18) · France (15) · South Korea (14) · Canada (12) · Germany (12) · Italy (12) · Turkey (Türkiye) (11) · Brazil (10) · Poland (10) · Belgium (9) · United Kingdom (9) · Georgia (8) · Greece (8)
Gino K In, MD (2) · Arya Amini (1) · Bhavana Konda (1) · Chukwuemeka Ikpeazu, MD (1) · Cynthia Gay, MD (1) · Debika Bhattacharya, MD (1) · Eric Christenson, MD (1) · Gregory P Botta, MD, PhD (1) · Gulam Manji, MD,PhD (1) · Jaymes Holland (1) · Jeffrey Skolnik, MD (1) · Jennifer W Carlisle (1) · Jochen H Lorch, MD (1)
PMID 29863979, PMID 32554615, PMID 35175355, PMID 27879972, PMID 31585957, PMID 31951149, PMID 31952975, PMID 33146741, PMID 33581821, PMID 33768419, PMID 33831732, PMID 33929394, PMID 33942954, PMID 34000246, PMID 34187851, PMID 34413166, PMID 34850166, PMID 35065058, PMID 35139273, PMID 35922251, PMID 36008722, PMID 36094839, PMID 36308296, PMID 36898933, PMID 37001859, PMID 37348996, PMID 37591293, PMID 37839734, PMID 37875144, PMID 37922910, PMID 38072158, PMID 38449916, PMID 38471711, PMID 38820979, PMID 38900987, PMID 39031963, PMID 39073799, PMID 39245360, PMID 39422598, PMID 39437804, PMID 39652449, PMID 39797702, PMID 40118215, PMID 40454639, PMID 40991883, PMID 41137728, PMID 41808570, PMID 41811823, PMID 42811017
2023 (8), 2016 (6), 2017 (4), 2019 (4), 2015 (2), P30CA014089 (2), P30CA033572 (2), P30CA138292 (2), P50CA186781 (2), R01CA262613 (2), U10CA180868 (2), UM1CA186691 (2), 2025 (1), P30CA060553 (1), U10CA180821 (1)